肝性脑病动物模型研究进展*

doi:10.3969/j.issn.1672-5069.2025.02.040

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (2): 316-319.doi: 10.3969/j.issn.1672-5069.2025.02.040

• 综述 • 上一篇

肝性脑病动物模型研究进展^*

杨雪梦, 尹东豪综述, 胡建华审校

100069 北京市首都医科大学附属北京佑安医院中西医结合中心

收稿日期:2024-08-19 出版日期:2025-03-10 发布日期:2025-03-11
通讯作者: 胡建华,E-mail:hjhdoc@ccmu.edu.cn
作者简介:杨雪梦,女,25岁,硕士研究生。主要从事中西医结合防治肝病研究。E-mail: xuemeng-yang@mail.ccmu.edu.cn
基金资助:
^*北京市扬帆计划重点医学专业-中西医结合重症肝病研究项目(编号:ZYLX201819);中西医结合防治传染病临床与基础研究-中西医专项课题资助项目(编号:BJYY-YN2022-32)

Animal models of hepatic encephalopathy

Yang Xuemeng, Yin Donghao, Hu Jianhua

Center for Integrative Chinese and Western Medicine, You'an Hospital, Capital Medical University, Beijing 100069, China

Received:2024-08-19 Online:2025-03-10 Published:2025-03-11

摘要/Abstract

摘要： 肝性脑病(HE)是肝脏疾病常见的并发症。由于HE发病机制复杂,通常使用动物模型研究HE发病的病理生理机制,以探讨潜在的治疗策略。随着现代科技的进步,HE动物模型得到了显著的改进和发展。本文结合最新研究成果,综述了HE动物模型的建立、评估、应用、局限性和未来应用前景,旨在为HE的治疗探索新的方法。

关键词: 肝性脑病, 动物模型, 评估

Abstract: Hepatic encephalopathy (HE) is a common complications of severe liver disease, with high recurrence rate and hard to deal with. Animal models are frequently employed in research to investigate pathophysiological mechanisms and explore potential therapeutic strategies. With advancements in modern medical technology, animal models for HE research have undergone remarkable improvements. In this review, we reviewed the latest research progress, focusing on establishment, evaluation, application, limitations, and future prospects of animal models in this field, with aiming to explore new therapeutic approaches for HE.

Key words: Hepatic encephalopathy, Animal models, Evaluation

杨雪梦, 尹东豪, 胡建华. 肝性脑病动物模型研究进展^*[J]. 实用肝脏病杂志, 2025, 28(2): 316-319.

Yang Xuemeng, Yin Donghao, Hu Jianhua. Animal models of hepatic encephalopathy[J]. Journal of Practical Hepatology, 2025, 28(2): 316-319.

参考文献

[1] Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs, 2019, 79(Suppl 1): 5-9.
[2] Rose CF, Amodio P, Bajaj JS, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol, 2020, 73(6): 1526-1547.
[3] Bellafante D, Gioia S, Faccioli J, et al. Old and new precipitants in hepatic encephalopathy: a new look at a field in continuous evolution. J Clin Med, 2023, 12(3): 1187.
[4] Ochoa-Sanchez R,Tamnanloo F, Rose CF. Hepatic encephalopathy: from metabolic to neurodegenerative. Neurochem Res, 2021, 46(10): 2612-2625.
[5] Hadjihambi A, Arias N, Sheikh M, et al. Hepatic encephalopathy: a critical current review. Hepatol Int, 2018, 12(Suppl 1): 135-147.
[6] Thabut D, Bouzbib C, Meunier L, et al. Diagnosis and management of hepatic encephalopathy: the French recommendations. Liver Int, 2023, 43(4): 750-762.
[7] Zhai H, Zhang J, Shang D, et al. The progress to establish optimal animal models for the study of acute-on-chronic liver failure. Front Med (Lausanne), 2023, 10: 1087274.
[8] Sepehrinezhad A, Shahbazi A, Sahab Negah S, et al. Drug-induced-acute liver failure: a critical appraisal of the thioacetamide model for the study of hepatic encephalopathy. Toxicol Rep, 2021, 8: 962-970.
[9] Abdel-Rafei M, Amin MM, Hasan HF. Novel effect of daflon and low-dose γ-radiation in modulation of thioacetamide-induced hepatic encephalopathy in male albino rats. Hum Exp Toxicol, 2017, 36(1): 62-81.
[10] Tsai CY, Su CH, Chan JY, et al. Nitrosative stress-induced disruption of baroreflex neural circuits in a rat model of hepatic encephalopathy: a DTI study. Sci Rep, 2017, 7: 40111.
[11] Jia W, Liu J, Hu R, et al.Xiaochaihutang improves the cortical astrocyte edema in thioacetamide-induced rat acute hepatic encephalopathy by activating NRF2 pathway. Front Pharmacol, 2020, 11: 382.
[12] Bai Y, Wang S, Wu F, et al. The changes of mitochondria in substantianigra and anterior cerebral cortex of hepatic encephalopathy induced by thioacetamide. Anat Rec (Hoboken), 2019, 302(7): 1169-1177.
[13] Khanna A, Trigun SK.Resveratrol normalizes hyperammonemia induced proinflammatory and pro-apoptotic conditions in rat brain. Int J Complement Altern Med, 2016, 4: 00115.
[14] 郑鋆. TAA诱导的A型肝性脑病大鼠肠道通透性改变及机制研究. 辽宁医学杂志, 2021, 35(05): 1-5.
[15] DeMorrow S,Cudalbu C, Davies N, et al. 2021 ISHEN guidelines on animal models of hepatic encephalopathy. Liver Int, 2021, 41(7): 1474-1488.
[16] Liu R, Kang JD, Sartor RB, et al. Neuroinflammation in murine cirrhosis is dependent on the gut microbiome and is attenuated by fecal transplant. Hepatology, 2020, 71(2): 611-626.
[17] Liu R, Ahluwalia V, Kang JD, et al. Effect of increasing age on brain dysfunction in cirrhosis. HepatolCommun, 2018, 3(1): 63-73.
[18] Vairappan B, Sundhar M, Srinivas BH. Resveratrol restores neuronal tight junction proteins through correction of ammonia and inflammation in CCl4-induced cirrhotic mice. Mol Neurobiol, 2019, 56(7): 4718-4729.
[19] Haeger P, Bouchet A,Ossandon C, et al. Treatment with melatonin improves cognitive behavior and motor skills in a rat model of liver fibrosis. Ann Hepatol, 2019, 18(1): 101-108.
[20] 逄菲, 胡瑾华. 肝性脑病的动物模型及分子生物学机制研究进展. 国际消化病杂志, 2014, 34: 84-86.
[21] Gonçalves DF, Tassi CC, Amaral GP, et al. Effects of caffeine on brain antioxidant status and mitochondrial respiration in acetaminophen-intoxicated mice.Toxicol Res (Camb), 2020, 9(5): 726-734.
[22] Saad MA,Rastanawi AA, El-Yamany MF. Alogliptin abates memory injuries of hepatic encephalopathy induced by acute paracetamol intoxication via switching-off autophagy-related apoptosis. Life Sci, 2018, 215: 11-21.
[23] Vigo MB, Pérez MJ, De Fino F, et al. Acute acetaminophen intoxication induces direct neurotoxicity in rats manifested as astrogliosis and decreased dopaminergic markers in brain areas associated with locomotor regulation.Biochem Pharmacol, 2019, 170: 113662.
[24] Heidari R,Jamshidzadeh A, Niknahad H, et al. Effect of taurine on chronic and acute liver injury: focus on blood and brain ammonia. Toxicol Rep, 2016, 3: 870-879.
[25] McGill MR, Williams CD, Xie Y, et al. Acetaminophen-induced liver injury in rats and mice: comparison of protein adducts, mitochondrial dysfunction, and oxidative stress in the mechanism of toxicity.Toxicol Appl Pharmacol, 2012, 264(3): 387-394.
[26] 何巧燕, 王知平, 王芳. 龙胆苦苷对D-氨基半乳糖联合脂多糖诱导的慢性肝损伤模型小鼠的保护作用. 山西中医药大学学报, 2022, 23(03): 168-172.
[27] Cauli O, González-Usano A, Cabrera-Pastor A, et al. Blocking NMDA receptors delays death in rats with acute liver failure by dual protective mechanisms in kidney and brain. Neuromolecular Med, 2014, 16(2): 360-375.
[28] Megaraj V, Ding X, Fang C, et al. Role of hepatic and intestinal p450 enzymes in the metabolic activation of the colon carcinogen azoxymethane in mice. Chem Res Toxicol, 2014, 27(4): 656-662.
[29] McMillin MA, Frampton GA, Seiwell AP, et al. TGFβ1 exacerbates blood-brain barrier permeability in a mouse model of hepatic encephalopathy via upregulation of MMP9 and downregulation of claudin-5. Lab Invest, 2015, 95(8): 903-913.
[30] Rose C, Michalak A, Pannunzio M, et al. Mild hypothermia delays the onset of coma and prevents brain edema and extracellular brain glutamate accumulation in rats with acute liver failure. Hepatology, 2000, 31(4): 872-877.
[31] Kristiansen RG, Lindal S, Myreng K, et al. Neuropathological changes in the brain of pigs with acute liver failure. Scand J Gastroenterol, 2010, 45(7-8): 935-943.
[32] Gandhi CR, Murase N, Subbotin VM, et al. Portacaval shunt causes apoptosis and liver atrophy in rats despite increases in endogenous levels of major hepatic growth factors. J Hepatol, 2002, 37(3): 340-348.

肝性脑病动物模型研究进展^*

Animal models of hepatic encephalopathy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱亭亭, 陈逸云, 谢帆慈, 李正鑫. 无创评估肝纤维化逆转研究进展^*[J]. 实用肝脏病杂志, 2025, 28(2): 169-172.
[2]	陈海琳, 杨涛, 周云. 原发性肝癌患者双源CT全肝灌注成像特点及对TACE术后残余病灶的评估价值^*[J]. 实用肝脏病杂志, 2024, 27(5): 769-772.
[3]	李钟浙, 廖晖, 徐小平. 肝硬化患者营养评价及饮食管理研究进展[J]. 实用肝脏病杂志, 2023, 26(4): 601-604.
[4]	邓珂欣, 罗红春. 常用血液学指标评定慢加急性肝衰竭患者并发细菌感染和预后价值研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 242-245.
[5]	李苏苏, 董媛, 贾浩延, 秦颖. 门冬氨酸鸟氨酸联合结肠透析治疗肝性脑病患者疗效及其对血浆β-EP和LPS的影响^*[J]. 实用肝脏病杂志, 2023, 26(1): 75-78.
[6]	刘南南, 李卫, 赵守松. 简化版动物命名试验对肝硬化并发轻微性肝性脑病的诊断价值及相关因素分析^*[J]. 实用肝脏病杂志, 2023, 26(1): 83-86.
[7]	邬政宏, 吴冬秋, 刘四斌. DCE-MRI诊断原发性肝癌效能和TACE术后评估肿瘤活性应用价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 881-884.
[8]	李文聪, 张潇潇, 南月敏. 噬血细胞综合征诊治进展[J]. 实用肝脏病杂志, 2022, 25(5): 612-615.
[9]	付丽红, 高月求, 王晓琳, 刘坤, 李曼, 黄凌鹰. 38例药物性肝损伤患者肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 512-516.
[10]	张岚, 李妍, 杨宁, 荆晶, 刘爱霞, 黄雨欣, 李伯安. 红细胞分布宽度和中性粒细胞/淋巴细胞比值评估原发性胆汁性胆管炎患者肝损伤临床价值研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 367-370.
[11]	李艳乐, 刘笑宇, 姚建宁, 王春峰, 张连峰, 张学秀. 乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 74-78.
[12]	黄力鸥, 吴春荣, 徐丹, 崔宇慧, 唐建国. 无肝素化连续性肾脏替代治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(6): 875-878.
[13]	张译之, 张晓慧, 陈煜. 非酒精性脂肪性肝病动物模型研究进展^*[J]. 实用肝脏病杂志, 2021, 24(5): 761-764.
[14]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.
[15]	曾娇, 郭贵海. 聚乙二醇与乳果糖治疗肝性脑病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2021, 24(1): 99-102.